Ionis Pharmaceuticals (NASDAQ:IONS) is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.
Since its founding in 1989 by Dr. Stanley T. Crooke, Ionis has advanced more than 40 investigational drugs into clinical development, successfully bringing several treatments to market through strategic partnerships. Notably, the company collaborated with Biogen on the launch of Spinraza® (nusinersen), the first approved treatment for spinal muscular atrophy, and has licensed other products to global biopharmaceutical companies such as AstraZeneca and Roche. Ionis also established Akcea Therapeutics as a subsidiary to commercialize assets in rare diseases, reflecting its commitment to specialized patient populations.
Headquartered in Carlsbad, California, Ionis operates research and development centers in the United States and maintains partnerships that enable commercial reach in North America, Europe and Asia-Pacific regions. The company employs teams of scientists, clinicians and manufacturing experts to advance RNA-modulating therapies from early discovery through late-stage clinical trials. Ionis’ integrated manufacturing capabilities support both internal programs and external collaborations, reinforcing its role as a leader in oligonucleotide production.
Under the leadership of Executive Chairman Stanley T. Crooke and President & Chief Executive Officer Brett P. Monia, Ionis continues to invest in next-generation RNA platforms, including ligand-conjugated ASOs and splice-modulating compounds. The company’s strategic focus on precision medicine and its platform-derived pipeline position Ionis to address unmet medical needs and expand the application of RNA-targeted therapies worldwide.
